Antibiotic Treatment Is Not Effective in Patients Infected With <i>Helicobacter pylori</i> Suffering From Extragastric MALT Lymphoma

Grünberger, Birgit; Wöhrer, Stefan; Streubel, Berthold; Formanek, Michael; Petkov, Ventzislav; Puespoek, Andreas; Haefner, Michael; Hejna, Michael; Jaeger, Ulrich; Chott, Andreas; Raderer, Markus

doi:10.1200/jco.2005.02.9025

Cited by 84 publications

(69 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,[16][17][18][19] In a retrospective analysis, Grünberger et al 24 have assessed the potential of HP eradication to induce responses in patients with extragastric MALT lymphoma. Out of a total of 77 patients, 16 had undergone HP eradication with metronidazole and clarithromycin as initial therapy for the lymphoma, including 5 patients with OAML.…”

Section: Oamlmentioning

confidence: 99%

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

Kiesewetter

Raderer

2013

Blood

Self Cite

View full text Add to dashboard Cite

Although antibiotic therapy has been established as the standard of care in patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, much less is known about the value of antibiotic therapy in nongastrointestinal (non-GI) MALT lymphomas. A computerized search (Medline) accompanied by a manual search to identify clinical reports on the topic of antibacterial therapy in patients with non-GI MALT lymphomas was performed. The majority of data were available for MALT lymphoma of the ocular adnexa (OAML) including a total of 131 patients in 4 retrospective studies, 3 prospective series (including 81 patients), and 1 case report. Treatment was exclusively targeting Chlamydophila psittaci (CP), using doxycycline in all but 2 studies. The median follow-up for these studies was 25 months, and both CP-positive as well as CP-negative patients responded. Complete remission was achieved in 23 patients (18%), 36 (27%) had a partial remission, 55 (42%) had stable disease, and 8 patients (6%) had progressive disease accounting for an overall response rate of 45%. In the largest study, a better response was suggested in CP-positive patients. By contrast, only scattered reports could be found for other non-GI localizations, allowing no conclusion about the benefit of antibiotic therapy and probably resulting in a publication bias toward positive cases. Based on these results, antibiotic therapy using doxycycline appears to be a reasonable first-line therapy for patients with OAML. Antibiotics, however, remain experimental for the time being in patients with other non-GI MALT lymphomas. Further preclinical studies as well as large-scale therapeutic trials are warranted to define the role of antibiotic therapy in such patients.

show abstract

Section: Oamlmentioning

confidence: 99%

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

Kiesewetter

Raderer

2013

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…2 In general, these extragastric lymphomas seem to be independent of HP; therefore, HP eradication therapy is, despite various case reports, 16,17 regarded as an ineffective treatment strategy in such patients. 18 As opposed to HP-associated gastric MALT lymphomas, the underlying stimulus for lymphoma development cannot be entirely removed in AD patients, as no causative therapy exists for AD. Thus, one could potentially expect an adverse effect of AD on the clinical course and the relapse rate in such patients.…”

Section: Introductionmentioning

confidence: 99%

MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course

et al. 2007

View full text Add to dashboard Cite

MALT lymphoma, especially of extragastric origin, is thought to be associated with an underlying autoimmune disease (AD) in a significant proportion of patients. No systematic assessment of the clinical characteristics of MALT lymphoma arising in AD as opposed to patients without AD has been performed so far. Therefore, all patients diagnosed and treated for MALT lymphoma at our institution have prospectively undergone routine clinical and serological assessment for AD since 1997. In total, 158 patients were available for analysis, and 61 out of 158 patients (39%) were diagnosed with an underlying AD. Patients with AD were predominantly women and significantly younger at lymphoma diagnosis (56 versus 67 years, P ¼ 0.004), with a significantly higher rate of extragastric lymphomas (P ¼ 0.012). Furthermore, lymphomas in these patients showed a lower frequency of trisomy 3 (P ¼ 0.04) and a significantly lower response rate to Helicobacter pylori eradication therapy in the case of gastric lymphomas (P ¼ 0.03). All other parameters including estimated median time to relapse were comparable between both groups. Our data suggest that patients with AD develop MALT lymphoma significantly earlier in life. The clinical course, however, does not appear to be adversely influenced by the presence of AD, as neither rate of relapse nor times to relapse or survival are significantly different.

show abstract

“…6,7 In contrast, empirical antibiotic treatment frequently fails in MZL when the targeted pathogens cannot be detected. 8 Since no potentially causative infectious agent was identified in two of our MZL cases, the presence of Abbreviation: n/a: not applicable.…”

mentioning

confidence: 99%

The peripheral helper T-cell repertoire in untreated indolent B-cell lymphomas: evidence for antigen-driven lymphomagenesis

et al. 2008

View full text Add to dashboard Cite

Antibiotic Treatment Is Not Effective in Patients Infected With Helicobacter pylori Suffering From Extragastric MALT Lymphoma

Cited by 84 publications

References 22 publications

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course

The peripheral helper T-cell repertoire in untreated indolent B-cell lymphomas: evidence for antigen-driven lymphomagenesis

Contact Info

Product

Resources

About